Croma-Pharma
Martin Scholler has a diverse work experience in the pharmaceutical and biotech industries. Martin is currently working as the Head of Manufacturing Science and Validation Engineering at Croma Pharma since 2022. Before that, they worked at Takeda from 2019 to 2022, where they held various roles including Associate Director, Principal Validation Scientist, and PV and Control Strategy Lead. Prior to Takeda, Martin worked at Shire as the Head of PV Strategy EU and Supervisor Process Validation Strategy Recombinant EU from 2015 to 2019. Martin also has experience as a Validation Specialist at Baxter Bio Science from 2011 to 2014. Martin started their career as a Diplomant at AIT Austrian Institute of Technology GmbH from 2010 to 2011.
From 2006 to 2011, Martin Scholler attended Fachhochschule Technikum Wien, where they pursued a Master's degree in Gesundheits- und Rehabilitationstechnik.
This person is not in any offices
Croma-Pharma
4 followers
Croma is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads and biostimulators complemented by its own skincare brand. Founded in 1976 by a pharmacist couple, Croma-Pharma GmbH is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US, Canada, China, Australia and New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.